Skip to main content

Table 3 Details of CRS and HIPEC

From: Feasibility and outcomes of cytoreductive surgery and HIPEC for peritoneal surface malignancies in low- and middle-income countries: a single-center experience of 232 cases

Operative time [mean ± SD] 379.9 ± 108.7 min  
PCI [mean (range)] Total (n=232) 9.3 (0–26)
- Non-ovarian group (n=101)
- Ovarian group (n=131)
- 11.1 (0–25)
- 7.9 (0–26)
Extent of peritonectomy Total peritonectomy
Disease-specific peritonectomy
49 (21.1%)
183 (78.9%)
Types of CRS Optimal CRS (CC-0/CC-1)
Suboptimal CRS (CC-2/CC-3)
219 (94.4%)
13 (5.6%)
Multivisceral resections Hysterectomy/salpingo-oophorectomy
Appendicectomy
Colectomy
Anterior/low-anterior resection
Small intestine -- resection/anastomosis
Splenectomy +/- distal pancreatectomy
Cholecystectomy
Urinary bladder–partial resection
42 (18.1%)
38 (16.4%)
22 (9.5%)
3 (1.3%)
21 (9.1%)
8 (3.5%)
16 (6.9%)
4 (1.7%)
Total 57 (24.5%)
Drugs for HIPEC Cisplatin
Mitomycin C
Oxaliplatin
Adriamycin
Melphalan
191 (82.3%)
27 (11.6%)
7 (3.0%)
5 (2.2%)
2 (0.9%)
ICU stay 1.3 (1–12) days  
Postoperative hospital stay 8.1 (5–26) days